-

Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina

Nearly all of Illumina’s claims to be dismissed as filed

PALO ALTO, Calif--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, issued the following statement today regarding the favorable recommendation by U.S. District Court Magistrate Judge Christopher J. Burke that nearly all claims brought by Illumina against Guardant Health in a lawsuit filed on March 17, 2022, be dismissed:

“We are pleased with Judge Burke’s recommendation that nearly all of Illumina’s claims be dismissed as filed. We continue to believe that Illumina has no basis for challenging the ownership of our patents and that this lawsuit is nothing more than an attempt to impede our mission to improve cancer care and save patients’ lives.”

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™ and GuardantINFINITY™ for advanced-stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

Contacts

Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417

Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035

Guardant Health, Inc.

NASDAQ:GH

Release Versions

Contacts

Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417

Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035

More News From Guardant Health, Inc.

Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. clinical launch of Guardant Reveal® Ultra, a new molecular residual disease (MRD) platform for solid tumors offering personalized, ultra-sensitive detection of residual cancer. Built on Guardant’s Smart Platform, Reveal Ultra incorporates tumor-informed, patient-specific genomic alterations to provide one of the most advanced and actionable views of MRD. Validat...

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 13, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 86,192 shares of its common stock to 118 new non-executive employees with a grant date of November 9, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The...

Guardant Health Prices $500 Million Convertible Senior Notes Offering

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its offering of $500 million aggregate principal amount of 0% convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuance and sale of the n...
Back to Newsroom